0001140361-23-036103.txt : 20230725
0001140361-23-036103.hdr.sgml : 20230725
20230725175648
ACCESSION NUMBER: 0001140361-23-036103
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230725
FILED AS OF DATE: 20230725
DATE AS OF CHANGE: 20230725
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALSTODT LANCE
CENTRAL INDEX KEY: 0001756228
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37603
FILM NUMBER: 231109619
MAIL ADDRESS:
STREET 1: BIORESTORATIVE THERAPIES, INC.
STREET 2: 40 MARCUS DRIVE, SUITE 1
CITY: MELVILLE
STATE: NY
ZIP: 11747
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioRestorative Therapies, Inc.
CENTRAL INDEX KEY: 0001505497
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
IRS NUMBER: 911835664
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 MARCUS DRIVE
CITY: MELVILLE
STATE: NY
ZIP: 11747
BUSINESS PHONE: (631) 760-8100
MAIL ADDRESS:
STREET 1: 40 MARCUS DRIVE
CITY: MELVILLE
STATE: NY
ZIP: 11747
FORMER COMPANY:
FORMER CONFORMED NAME: Stem Cell Assurance, Inc.
DATE OF NAME CHANGE: 20101110
4
1
form4.xml
X0508
4
2023-07-25
0001505497
BioRestorative Therapies, Inc.
BRTX
0001756228
ALSTODT LANCE
40 MARCUS DRIVE
MELVILLE
NY
11747
true
true
true
President, CEO, COB
false
Common Stock
2023-07-25
4
P
0
4200
2.44
A
184418
D
Stock Option
5.08
2031-03-18
Common Stock
293479
293479
D
Stock Option
5.08
2031-11-04
Common Stock
42059
42059
D
Stock Option
2.91
2033-02-17
Common Stock
106762
106762
D
This transaction was executed in multiple trades at prices ranging from $2.41 to $2.47 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected.
Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024.
The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
/s/ Lance Alstodt
2023-07-25